GlassScriptPhysician profile
Catherine L Glasgow
NPI 1205228012
$3,845.12
in general payments reported to CMS, 2019-2025
45 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $542 · 2023: $936 · 2024: $1,112 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,303.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $543.61 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $385.97 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $255.87 | 2024-2025 | Recorlev |
| Amgen INC. | $180.03 | 2022-2025 | Repatha, Otezla, Tezspire |
| Merck Sharp & Dohme LLC | $165.38 | 2022-2025 | Verquvo, Belsomra |
| Otsuka America Pharmaceutical, INC. | $143.14 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $142.83 | 2023-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.31 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $129.01 | 2022-2024 | |
| Shield Therapeutics INC | $128.71 | 2024-2025 | |
| Axsome Therapeutics, INC. | $124.65 | 2024-2025 | Auvelity |
| Lilly USA, LLC | $122.64 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $90.24 | 2022-2023 | Trintellix |
| Mylan Specialty L.P. | $88.57 | 2023-2024 | Yupelri |
| Glaxosmithkline, LLC. | $83.57 | 2022-2024 | Trelegy Ellipta |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $76.93 | 2023-2025 | |
| Therapeuticsmd, INC. | $61.07 | 2022 | |
| Janssen Pharmaceuticals, INC | $60.98 | 2023-2024 | Xarelto, Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $59.46 | 2022 | |
| Lundbeck LLC | $59.06 | 2024-2025 | Rexulti |
| Viatris Specialty LLC | $56.11 | 2025 | Yupelri |
| Agile Therapeutics, INC. | $50.36 | 2022-2023 | Twirla |
| Phathom Pharmaceuticals, INC. | $50.22 | 2023-2024 | Voquezna |
| Ironwood Pharmaceuticals, INC | $47.20 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $46.52 | 2023 | Quviviq |
| Pfizer INC. | $44.91 | 2024-2025 | |
| Organon LLC | $43.22 | 2022-2025 | Nexplanon |
| Antares Pharma, INC. | $39.44 | 2023 | Nocdurna, Xyosted, Tlando |
| Exact Sciences Corporation | $39.31 | 2024-2025 | Cologuard Collection Kit |
| Verity Pharmaceuticals INC. | $36.66 | 2025 | Tlando |
| Abiomed | $35.56 | 2024 | Impella |
| Evofem Biosciences, INC. | $35.13 | 2022 | |
| Nalu Medical, INC. | $32.02 | 2025 | Nalu Neurostimulation System |
| Recordati_rare_diseases_inc. | $30.61 | 2025 | Isturisa |
| Halozyme INC | $28.40 | 2023 | |
| Tempus Ai, INC | $26.61 | 2024 | |
| Nestle Healthcare Nutrition INC. | $25.04 | 2023 | |
| Daiichi Sankyo INC. | $24.99 | 2024 | Injectafer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.51 | 2024 | Caplyta |
| Myovant Sciences INC. | $19.94 | 2022 | |
| Corcept Therapeutics | $18.43 | 2025 | Korlym |
| Dexcom, INC. | $15.40 | 2025 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $15.30 | 2025 | Nuzyra |
| Astellas Pharma US INC | $15.03 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $14.17 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Glasgow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.